The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.

导出 LinkOut

翻译打印收藏纠错

第一作者： Huan,Zhou

第一单位： Department of Pharmacy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China; Pharmaceutical College, Guangxi Medical University, Nanning, China.

作者： Huan,Zhou ^[1] ; Li-Xiang,Fu ^[2] ; Li,Li ^[3] ; Yan-Yan,Chen ^[4] ; Hong-Qing,Zhu ^[5] ; Jin-Ling,Zhou ^[5] ; Mei-Xian,Lv ^[5] ; Ri-Zhi,Gan ^[5] ; Xuan-Xuan,Zhang ^[5] ; Gang,Liang ^[6]

作者单位： Department of Pharmacy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China; Pharmaceutical College, Guangxi Medical University, Nanning, China. ^[1] Department of Pharmacy, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou, China. ^[2] College of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China. ^[3] Department of Pharmacy, The Second People's Hospital of Qinzhou, Qinzhou, China. ^[4] Pharmaceutical College, Guangxi Medical University, Nanning, China. ^[5] Pharmaceutical College, Guangxi Medical University, Nanning, China. Electronic address: lianggang@gxmu.edu.cn. ^[6]

关键词 5,3′,4′,3″,4″,5″-6-O-ethyl-EGCG (Y6)Antitumor effect Cardiotoxicity Daunorubicin (DNR)Epigallocatechin gallate (EGCG)Human carbonyl reductase 1 (CBR1)